695 karma · joined September 1, 2009
brian.endofmyusername@pepsico.com (for work related stuff) or brian@endofmyusername.me for personal/hacker stuff.
PepsiCo eCom Senior Front End Engineer: https://www.pepsicojobs.com/main/jobs/217236BR?lang=en-us&pr...
PepsiCo eCom Back End Engineer: https://www.pepsicojobs.com/main/jobs/216201BR?lang=en-us&pr...
PepsiCo eCom Senior Data Engineer: https://www.pepsicojobs.com/main/jobs/218207BR?lang=en-us&pr...
PepsiCo eCom Full Stack Engineer: https://www.pepsicojobs.com/main/jobs/219150BR?lang=en-us&pr...
PepsiCo eCom Senior Infrastructure Engineer: https://www.pepsicojobs.com/main/jobs/219153BR?lang=en-us&pr...
Pepsi eCom functions mostly like a startup within Pepsi Corporate, and our primary languages are Elixir for applications and Python for data engineering work. If you are interested or have any questions not answered by the pepsicojobs.com website, feel free to reach out to me with questions and I can try and help answer or connect you to someone in our team to discuss.
Specifically this line: > Or, as a paper published Tuesday in Science suggested, it could trace back to previous encounters with other coronaviruses, such as those that cause the common cold.
a) current hypothesis is people with prior exposure to common-cold non-COVID-19 coronaviruses are by and large either asymptomatic or have milder symptoms than those without such exposure
b) presumably it should be possible to test people for these antibodies much as we can test people for COVID antibodies
If people would volunteer for the b) anti-body test in reasonable numbers, and a subset of them who have them would volunteer for a modified trial, we could possibly do a double-blind intentional-exposure test on people to confirm that the vaccine confers BETTER immunity than the existing similar antibodies do, right? Would it be possible to ethically and realistically use that strategy to accelerate effectiveness testing (if not safety testing) of any vaccine candidates? or would the smaller scale of that have only made sense for something more like Phase 2 trials?
Arguably, as long as safety is near perfect, we should be willing to tolerate only moderate (say, 90%) effectiveness (and I'd read one of the vaccines took two doses to get 100% effectiveness but was 90% after a single dose), but I don't know how safety is evaluated and obviously long-term safety and short-term safety are pretty different/I imagine a lot of people will be more concerned about long term safety and I don't know how you can reassure them on that on any kind of accelerated schedule.
Anyway, I think open source stuff sometimes needs constructive criticism but should always be appreciated first as a contribution to the ecosystem even if you're not personally planning to use it.
Today Timescale offers Timescale-as-a-service, so this allows them a kind of soft-monopoly on being a paid provider for this, but do these licenses generally contain a provision such that if they no longer provide that service themselves, whether from going out of business or a pivot to another product, then someone else could step in and offer it in the future? Closed source products have often had a kind of source-code escrow arrangement so that if they go out of business, you're not stuck unable to fix your own bugs, but similarly, if part of the value in adopting it is that the paid service IS available, knowing that someone else can offer a compatible service if they disappear might be a nice reassurance for the license to offer.
> In the same sense I don't think "machine x does y" expresses fewer facts than "machine x does y, and it is conscious".
brings to mind behaviorism, which was of course influential and compelling for a long time. The problem with behaviorism, if you want just one problem, is how do you even talk about something like Synesthesia within behaviorism? It's (initially) a purely subjective/qualia related experience. While behaviorism was in vogue, it was difficult to take Synesthesia seriously and it was dismissed as people being poetic and metaphorical, but those who experienced grapheme-color synaesthasia could see shapes present in a number-pattern readily that those without it could not see.Also, as a note, my first production Elixir service didn't talk to a relational DB at all, and was basically a thin API wrapper around ElasticSearch... others I know have basically used it just for realtime features connecting to browsers with WebSockets for push via Phoenix Channels (or now LiveView)... so even without any of those database adapters you may well find a use case it's a perfect fit for, and where lack of those adapters is not an impediment! Either way, good luck!
EDIT: couldn't find original blog post but this article seems to have some of the same math/details in less entertaining form https://blogs.ams.org/mathgradblog/2016/06/08/okcupid-math-o...